<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DALFOPRISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DALFOPRISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DALFOPRISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DALFOPRISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
